Assignee
ANGIEX INC
US·3 granted patents·9 pending applications·7 citations·filing 2018–2024
Top patents by PatentIndex Score
12 records- 0189US11208495B2Anti-TM4SF1 antibodies and methods of using sameANGIEX INC·Filed 2018·Granted Dec 28, 2021·7 cites·15 claims
- 0266US2022267461A1Anti-tm4sf1 antibodies and methods of using sameANGIEX INC·Filed 2021·Application pending·0 cites
- 0366US2022153860A1Anti-tm4sf1 antibodies and methods of using sameANGIEX INC·Filed 2021·Application pending·0 cites
- 0459US2025152730A1Anti-tm4sf1 antibody-drug conjugates comprising cleavable linkers and methods of using sameANGIEX INC·Filed 2024·Application pending·0 cites
- 0558US2024342302A1Degrader-antibody conjugates and methods of using sameANGIEX INC·Filed 2024·Application pending·0 cites
- 0658US2024156978A1Maytansine-antibody conjugates and methods of using sameANGIEX INC·Filed 2023·Application pending·0 cites
- 0757US2023372518A1Antimitotic tetrapeptide-antibody conjugates and methods of using sameANGIEX INC·Filed 2023·Application pending·0 cites
- 0856US2024166759A1Combinations comprising anti-tm4sf1 antibodies and immunotherapeutic agents and methods of using the sameANGIEX INC·Filed 2023·Application pending·0 cites
- 0952US2023293713A1Anti-tm4sf1 antibody drug conjugates and methods of using sameANGIEX INC·Filed 2022·Application pending·0 cites
- 1050US2023338572A1Anti-tm4sf1 antibody-drug conjugates comprising cleavable linkers and methods of using sameANGIEX INC·Filed 2023·Application pending·0 cites
- 1144US12458705B2Antibody-oligonucleotide conjugatesANGIEX INC·Filed 2019·Granted Nov 4, 2025·0 cites·12 claims
- 1242US12428477B2Antibody-drug conjugates comprising anti-TM4SF1 antibodies and methods of using the sameANGIEX INC·Filed 2020·Granted Sep 30, 2025·0 cites·7 claims
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →